Pyxis Oncology, Inc. (PYXS) Revenue History
Annual and quarterly revenue from 2019 to present
PYXS Revenue Over Time (2019–2025)
PYXS Revenue Growth History
0 of 1 years with positive growth- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- N/A
- FY2025 revenue growth
- -14.2%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q4 2025 | $11.0M | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $2.8M | — |
| Q1 2025 | $0 | -100.0% |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | — |
| Q2 2024 | $0 | — |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
PYXS's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
PYXS Revenue Analysis (2019–2025)
Current Revenue & Growth
As of June 12, 2026, Pyxis Oncology, Inc. (PYXS) generated trailing twelve-month (TTM) revenue of $13.9 million. The most recent quarter (Q1 2026) recorded $0 in revenue, down 100.0% sequentially.
Historical Growth Trajectory
PYXS's historical revenue data shows various trends over time. Pyxis Oncology, Inc.'s highest annual revenue of $16.1 million was recorded in 2024.
Revenue by Segment
PYXS's revenue is primarily driven by Milestone Revenue (100%). With over half of revenue concentrated in Milestone Revenue, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including RCUS (+67.4% YoY), AGIO (+78.3% YoY), and MGNX (+3.1% YoY). Compare PYXS vs RCUS →
PYXS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
 PYXSCurrent | $14M | - | - | -609.2% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 AGIO | $54M | +78.3% | - | -873.9% | |
 MGNX | $150M | +3.1% | +8.9% | -48.7% |
PYXS Historical Revenue Data (2019–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $13.9M | -14.2% | $11.5M | 82.8% | $-84,420,000 | -609.2% |
| 2024 | $16.1M | - | $15.7M | 97.1% | $-89,460,000 | -554.1% |
| 2023 | $0 | - | $0 | - | $-82,196,000 | - |
| 2022 | $0 | - | $0 | - | $-123,481,000 | - |
| 2021 | $0 | - | $0 | - | $-69,717,000 | - |
| 2020 | $0 | - | $-444,000 | - | $-12,894,000 | - |
| 2019 | $0 | - | $0 | - | $-2,879,000 | - |
What if you invested $1,000 in PYXS back in 2019?
Total return with dividends reinvested · 7+ years of data
Calculate ReturnsHow much would $100/month in PYXS be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs PYXS Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationPYXS vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowPYXS — Frequently Asked Questions
Quick answers to the most common questions about buying PYXS stock.
Is PYXS's revenue growth accelerating or slowing?
PYXS TTM revenue: $14M. YoY growth: N/A. 5-year CAGR: N/A.
What is PYXS's revenue history from 2019 to 2026?
Pyxis Oncology, Inc. (PYXS) revenue history spans 2019 to 2026. TTM revenue as of 2026 is $14M, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is PYXS's long-term revenue growth rate (CAGR)?
Pyxis Oncology, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for PYXS.
Why does PYXS's quarterly revenue fluctuate?
PYXS quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Pyxis Oncology, Inc.'s revenue data from 2019 to 2026 shows full historical quarterly detail on this page.
How is PYXS's revenue distributed by segment?
PYXS reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does PYXS's revenue compare to industry peers?
Pyxis Oncology, Inc. (PYXS) with TTM revenue of $14M and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.